Coagulopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Coagulopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-coagulation-factor-ix-and-drug-combination-for-patients-with-major-bleeding-on-factor-xa-inhibitor-therapy/ Wed, 29 Apr 2026 15:00:19 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-human-coagulation-factor-ix-and-drug-combination-for-patients-with-major-bleeding-on-factor-xa-inhibitor-therapy/ This clinical trial is focused on studying a treatment for patients experiencing acute major bleeding while on a specific type of blood thinner known as a direct oral anticoagulant (DOAC) that works by inhibiting factor Xa. The treatment being tested is called OCTAPLEX, which is a four-factor prothrombin complex concentrate. This treatment contains several important proteins, including human coagulation factors IX, II, VII, and X, as well as protein C and protein S. These proteins are essential for blood clotting and are used to help reverse the effects of the blood thinner in emergency situations.

The purpose of the study is to evaluate the effectiveness of OCTAPLEX in stopping major bleeding in patients who are taking a factor Xa inhibitor. Participants in the study will receive different doses of OCTAPLEX to determine which dose is more effective in managing the bleeding. The study will involve monitoring patients for a short period after receiving the treatment to observe any changes in their condition and to ensure their safety.

Throughout the study, researchers will assess the treatment’s ability to control bleeding and will also monitor for any side effects or complications. The study aims to provide valuable information on how to best manage bleeding in patients taking DOACs, ultimately improving care for those who experience this serious condition.

]]> Study on Coagulation Differences Using Fresh Frozen Plasma and Solvent-Detergent Plasma in Children Undergoing Congenital Heart Surgery https://clinicaltrials.eu/trial/study-on-coagulation-differences-using-fresh-frozen-plasma-and-solvent-detergent-plasma-in-children-undergoing-congenital-heart-surgery/ Wed, 29 Apr 2026 14:59:11 +0000 https://clinicaltrials.eu/trial/study-on-coagulation-differences-using-fresh-frozen-plasma-and-solvent-detergent-plasma-in-children-undergoing-congenital-heart-surgery/ This clinical trial is focused on studying blood clotting in children undergoing heart surgery. The study compares two types of plasma, which is a component of blood. The first type is called fresh frozen plasma, and the second type is Solvent-detergent plasma, known by the brand name Omniplasma. Plasma is important in helping blood to clot properly, which is crucial during and after surgery.

The purpose of the study is to investigate how these two types of plasma affect blood clotting in children who have heart surgery. The study will look at various factors related to blood clotting, such as the activity of certain proteins and the number of blood cells that help with clotting. These factors include protein S activity, α2-antiplasmin, and others like fibrinogen and thrombocyte count, which are important for understanding how well the blood can clot after surgery.

During the study, children undergoing heart surgery will receive either fresh frozen plasma or Omniplasma. The researchers will then measure the blood clotting factors shortly after the surgery to see if there are any differences between the two types of plasma. This information will help doctors understand which type of plasma might be better for children having heart surgery, ensuring they receive the best possible care.

]]>